The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9499589 B1

PDF
Full Text
Expired
Date of Patent:
Nov. 22, 2016

Filed:

May. 17, 2013
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Thomas August, Baltimore, MD (US);

Ernesto Marques, Jr., Baltimore, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/00 (2006.01); C07K 14/005 (2006.01); A61K 39/21 (2006.01); C07H 21/04 (2006.01); C12N 15/62 (2006.01); C12N 15/86 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 39/12 (2013.01); A61K 39/21 (2013.01); C07H 21/04 (2013.01); C12N 15/62 (2013.01); C12N 15/86 (2013.01); A61K 39/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/57 (2013.01); C07K 14/70596 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/06 (2013.01); C07K 2319/40 (2013.01); C12N 2740/16234 (2013.01); C12N 2750/14143 (2013.01);
Abstract

The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.


Find Patent Forward Citations

Loading…